STEP I: Patients with a history of prior malignancy are eligible provided they were treated with curative intent and do not require active therapy (currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast are not excluded)
Excluding the primary tumor leading to enrollment in this study, any other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within the past  months
Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past  months
Previous malignancy, except for non-squamous-cell carcinoma of skin or carcinoma in-situ of the uterine cervix, unless the tumor was treated with curative intent more than  years prior to study entry.
Active malignant disease relapse or other active malignancy with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Active malignancy (except for RCC or definitively treated basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past  months
Malignancy not in remission or w/in last  yrs (exceptions: basal or skin squamous cell carcinoma or in situ cervix cancer)
History of other malignancy (apart from basal cell carcinoma of the skin, or in situ cervix carcinoma) except if the patient has been free of symptoms and without active therapy during at least  years
Patients with a prior malignancy within the last  years (except for skin basal or squamous cell carcinoma, or in situ cancer of the cervix)
Prior history of malignancy, other than MDS or AML, unless the subject has been free of the disease for ? year prior to the start of study treatment However, subjects with the following history/concurrent conditions are allowed: basal or squamous cell carcinoma of the skin; carcinoma in situ of the cervix; carcinoma in situ of the breast; incidental histologic finding of prostate cancer
Other malignancy within the past  years, except for the following if treated and not active: basal cell or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ or International Federation of Gynecology and Obstetrics (FIGO) stage  carcinoma of the cervix
History (within  years prior to first study drug administration) of another malignancy unless the malignancy was treated with curative intent and likelihood of relapse is small. Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix may be enrolled.
No history of malignancy within  years of enrollment except for basal cell carcinoma of the skin, squamous cell skin cancer or carcinoma in situ of the cervix
History of malignancy, treated or untreated, within the past five years whether or not there is evidence of local recurrence or metastases, with the exception of basal cell carcinoma of the skin and cervical carcinoma in situ
Presence of other active invasive cancers other than the one treated in this trial within  years prior to screening, with the exception of appropriately treated basal-cell carcinoma of the skin, in situ carcinoma of the uterine cervix, or other local tumours considered cured by local treatment.
Being actively treated for a concurrent malignancy with the exception of basal cell carcinoma or carcinoma in situ of the cervix
Prior malignancy or myelodysplastic syndrome (active within  years of screening) except completely excised non-invasive basal cell or squamous cell carcinoma of the skin, and in situ squamous cell carcinoma of the cervix
Patients with a prior malignancy with in the last  years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
Other malignancies within the past  years (not including basal cell carcinoma of the skin, prostate cancer or in situ cervix carcinoma).
Patient has a history of another malignancy within  years prior to starting study treatment, except for cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
Any other malignancies within the past  years other than basal cell skin cancer or carcinoma in situ of the cervix
Prior malignancy with in the last  years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix or the breast, unless they are successfully treated with curative intent for more than  years before entering the study
Prior history of cancer within the last three years except for basal cell carcinoma of the skin or carcinoma in situ of the cervix; patients with previous malignancies but without evidence of disease for  years will be allowed to enter the trial
Patients with active concurrent malignancy, other than superficial, non-invasive squamous cell carcinoma of the skin or uterine cervix, within the past three years
Prior or simultaneous malignancy within the past  years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ, thyroid carcinoma, or low-risk prostate cancer); in-situ carcinoma is allowed
History of another malignancy within  years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
Prior malignancy (active within  years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix
History of another malignancy within  years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
Prior or simultaneous malignancies within the past two years (other than carcinoma in situ of the cervix, carcinoma in situ [CIS] of the colon, melanoma in situ, thyroid cancer, and basal cell or squamous cell carcinoma of the skin)
History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last  years.
History of malignant tumors other than KS, unless:\r\n* In complete remission for >=  year from the time response was first documented or\r\n* Completely resected basal cell carcinoma or\r\n* In situ squamous cell carcinoma of the cervix or anus
Past or present history of malignant tumors other than Kaposi sarcoma unless one of the following:\r\n* Complete remission for >=  year from completion of therapy\r\n* Completely resected basal cell carcinoma\r\n* In situ squamous cell carcinoma of the cervix or anus
Other malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy greater than or equal to  months prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the past  months: carcinoma in situ of the cervix, colorectal carcinoma in situ, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
Malignancy within last  years, except for basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix that has been successfully treated.
History of another malignancy within  years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
Previous malignancy with life expectancy less than  months or requiring systemic treatment (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
Patient has a history of another malignancy within  years prior to starting study treatment, except for cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix.
History of other malignancy (apart from basal cell carcinoma of the skin, or in situ cervix carcinoma) except if the patient has been free of symptoms and without active therapy for at least  years.
Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast.
History of another malignancy requiring active treatment within  years prior to starting study treatment, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
Prior malignancy of any type that occurred less than  years previously, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
Other active malignancy (except definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within past  months.
Patients must not have prior history of malignancy other than MDS (except basal cell or squamous skin cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been confirmed free of disease for >=  years
Known previous/current malignancy requiring treatment within ?  years except for cervical carcinoma in situ, squamous or basal cell skin carcinoma, and superficial bladder carcinoma.
Other active, invasive malignancy requiring ongoing therapy or expected to require systemic therapy within two years; localized squamous cell carcinoma of the skin, basal-cell carcinoma of the skin, carcinoma in-situ of the cervix, or other malignancies requiring locally ablative therapy only will not result in exclusion
Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast.
History of malignancy (other than SMM) within  years before the date of randomization, except for the following if treated and not active: basal cell or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of breast, or International Federation of Gynecology and Obstetrics (FIGO) Stage  carcinoma of the cervix
Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past  months
History of non-breast malignancies within the  years prior to study entry, except for carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin
Other malignancies within the past  years other than basal cell skin cancer or carcinoma in situ of the cervix
Any invasive malignancy within previous  years (other than basal cell carcinoma or cervical carcinoma in situ).
Patient with history of another malignancy within  years prior to starting study treatment, except for cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
History of another malignancy within  years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
Patients with an active malignancy requiring treatment in the next  months (except for basal or squamous cell carcinoma, or in situ cancer of the cervix or breast, and asymptomatic prostate cancer)
Patients with a history of basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix are eligible
Previous malignancy less than  years ago other than in situ carcinoma of the cervix, basal cell carcinoma or squamous carcinoma of the skin;
Presence of any other active malignancy or prior history of malignancy, except for: basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate carcinoma not requiring active treatment
Patients with a history of another malignancy within  years prior to registration are not eligible for participation; Note: the exceptions to this include cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
History of non-breast malignancies within the  years prior to randomization, except for carcinoma in situ (CIS) of the cervix, CIS of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin
Other malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy greater than or equal to  months prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the past  months: carcinoma in situ of the cervix, colorectal carcinoma in situ, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
Other active malignancy except for basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or bladder
History of other malignancy (apart from basal cell carcinoma of the skin, or in situ cervix carcinoma) except if the patient has been free of symptoms and without active therapy during at least  years.
Prior history of malignancy or a concurrent malignancy, with the exception of cutaneous basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, or in situ carcinoma of the uterine cervix, prostate, or breast, unless a complete remission was achieved at least  years prior to study entry and no additional therapy is required or anticipated to be required during the study period
Active malignancy (except for adenocarcinoma of the lung or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past months.
History of another malignancy within  years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix, or any tumor that is after clearing with the principal investigator (PI) clearly not considered to have impact on prognosis
Active cancer (either concurrent or within the last  years) that requires non-surgical therapy (e.g. chemotherapy or radiation therapy), with the exception of surgically treated basal or squamous cell carcinoma of the skin, melanoma in-situ, or carcinoma in-situ of the cervix.
Other malignancy (in addition to gastric cancer [GC]) within  years before enrollment, except for carcinoma in situ of the cervix or squamous or basal cell carcinoma of the skin that has been previously treated with curative intent
Other active, invasive malignancy requiring ongoing therapy or expected to require systemic therapy within two years; localized squamous cell carcinoma of the skin, basal-cell carcinoma of the skin, carcinoma in-situ of the cervix, or other malignancies requiring locally ablative therapy only will not result in exclusion
Patients with a prior malignancy within the last  years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
History of other clinically active malignancy within  years of enrollment, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix or breast
Patients who have been diagnosed with a second cancer (except carcinoma in situ of the cervix and basal cell carcinoma of the skin) which is currently active or has been treated within three years prior to screening
Other malignancies within the last  years, except for carcinoma in situ of the cervix or basal cell carcinoma
Other malignancy within the past  years, except for the following, if treated and not active: basal cell or nonmetastatic (non-spreading) squamous cell carcinoma of the skin, cervical carcinoma or International Federation of Gynecology and Obstetrics Stage  carcinoma of the cervix
Active second malignancy except localized prostate cancer, basal cell carcinoma of the skin and carcinoma in situ of the skin or cervix
Other malignancy (with the exception of cervical carcinoma in situ or basal cell carcinoma of the skin) for which there has been treatment within the last  years
History of another malignancy within the past five years, with the exception of basal skin carcinoma or cervical carcinoma in situ or completely resected colonic polyps carcinoma in situ
Past or present history of malignant tumors other than KS unless: a) in a complete remission for >=  year from the time a response was first documented; b) completely resected basal cell carcinoma; or c) in situ squamous cell carcinoma of the cervix or anus
Other than the primary malignancy, active cancer (either concurrent or within the last  years) that requires non-surgical therapy (e.g., chemotherapy or radiation therapy), with the exception of surgically treated basal or squamous cell carcinoma of the skin, melanoma in situ, or carcinoma in-situ of the cervix
Other malignancies within the past  years other than basal cell skin cancer or carcinoma in situ of the cervix
Second malignancy other than non-basal cell carcinoma of the skin or in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least two years previously and subject is in remission
History of another malignancy within  years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
Prior malignancy (active within  years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix
History of any other malignancy within  years (except basal cell carcinoma of the skin or carcinoma in situ of the cervix)
Presence or history of other neoplasms (treated during the last five years prior to study entry) other than carcinoma in situ of the cervix or basal carcinoma of the skin
History of other malignancy within the last  years, except for carcinoma in situ of the cervix or basal cell carcinoma of the skin
Previous malignancy within the past  years except for basal or squamous cell carcinoma of the skin, melanoma in-situ, and carcinoma in-situ of the cervix
Other malignancy within the last  years, except for carcinoma in situ of the cervix and basal or squamous cell carcinoma of the skin
History of second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix or the breast, unless the tumor was successfully treated with curative intent at least  years before trial entry
Other active, invasive malignancy requiring ongoing therapy or expected to require systemic therapy within two years; localized squamous cell carcinoma of the skin, basal-cell carcinoma of the skin, carcinoma in-situ of the cervix, or other malignancies requiring locally ablative therapy only will not result in exclusion
Had a malignancy within  years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated;
No non-breast malignancy within the past  years other than treated squamous or basal cell carcinoma of the skin or carcinoma in situ (CIS) of the cervix
Any previous malignancy treated with curative intent and the subject has been disease free for less than  years prior to randomization, with exception of Carcinoma?in?situ of the cervix, Squamous carcinoma of the skin, Basal cell carcinoma of the skin.
Basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix within the past five years treated with curative intent. History of prior malignancy are eligible if disease-free for > years.
Patients with a prior malignancy within the last  years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
Other past or current malignancy (with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix or breast) unless the tumour was successfully treated with curative intent at least  years prior to trial entry.*
Potential participants who meet any of the following criteria will be excluded from participating in the study: Prior exposure to trabectedin or dacarabazine, less than  weeks from last dose of systemic cytotoxic therapy, radiation therapy, or therapy with any investigational agent, other malignancy within past  years. Exceptions: basal or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, or Federation Internationale de Gynecologie et d'Obstetrique (FIGO) Stage  carcinoma of the cervix
Potential participants who meet any of the following criteria will be excluded from Participating in the study: Prior exposure to trabectedin, less than  weeks from last dose of systemic cytotoxic therapy, radiation therapy, or therapy with any investigational agent, other malignancy within past  years. Exceptions: basal or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, or Federation Internationale de Gynecologie et d'Obstetrique (FIGO) Stage  carcinoma of the cervix does not apply
History of other malignancy unless the malignancy has been in remission without treatment for >/= years prior to enrolment, and except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lymphectomy alone
Patients with another malignancy, unless they have been disease free for  years prior to registration, with the exception of\r\n* Basal cell or non-metastatic squamous cell carcinoma of the skin\r\n* Cervical carcinoma in situ or International Federation of Gynecology and Obstetrics (FIGO) stage  carcinoma of the cervix
History of other clinically active malignancies within  years, except for carcinoma in situ of the cervix, basal cell carcinoma, or squamous carcinoma of the skin.
Other active malignancy (except definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past  months
Patients with a known prior malignancy who have received systemic chemotherapy within five years, except basal cell carcinoma of the skin, carcinoma in situ of the cervix, prior HCC, and patients with liver mass(es) proven to be metastatic disease are excluded
Patients with a previous malignancy within the past  years (other than curatively treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, or any cancer that is considered to be cured and have no impact on PFS and OS for the current NSCLC).
Active malignancy (except for DTC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past  months.
Other active invasive malignancy (except for treated basal or squamous cell skin carcinoma, or in situ cervix carcinoma).